MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Metastases
Related studies linked through entity extraction aliases.
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
- Status
- COMPLETED
- Phase
- PHASE2
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Iressa Expanded Access Program (EAP)
- Status
- COMPLETED
- Phase
- PHASE3
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1